Online inquiry

IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9956MR)

This product GTTS-WQ9956MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9956MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4881MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ3802MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2121MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ10517MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ12458MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12027MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ14177MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ14892MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW